Click through a quick summary of the key changes made to the CDC's Advisory Committee on Immunization Practices' 2020 recommendations for adults.
The Advisory Committee on Immunization Practices of the CDC released the 2020 recommended immunization schedule for adults. In addition to revised administration recommendations for 8 vaccines, a blue footnote key was added to indicate that shared clinical decision-making beteween physician and patient is recommended; the footnote was added to recommendations for HPV, pneumococcal conjugate vaccine (PCV13), and meningococcal vaccination.Click through the slides below for a quick review of the updates.
Hepatitis A Vaccination. The primary changes to this recommendation are small revisions for the pregnancy indication, addition of a recommendation for vaccination in settings of exposure, and removal of clotting factor disorders as an indication for the vaccination.
Hepatitis B Vaccination.Minor changes were made for the pregnancy indication, including addition of patients at risk for infection or severe outcome during gestation and reomval of the recommendation for use of Heplisav-B administration for lack of safety data.
Human papillomavirus (HPV) Vaccination. The note was changed to indicate that the HPV vaccination is recommended for all persons through age 26 years. A subsection was added on shared clinical decision-making for persons aged 27-45 years.
Influenza Vaccination. A bulleted list was added to indicate when the live attenuated infuenza vaccine should not be used. Minor edits were made to guidance for persons with a history of Guillain-BarrÃ© syndrome.
Measles, Mumps, & Rubella (MMR) Vaccination. Revisions were made to clarify ACIP recommendations for healthcare personnel with separate bullets for those with no evidence of immunity born either in or after 1957 and those born before 1957.
Meningococcal Vaccination. A shared clinical decision-making subsection was added that includes a bullet for adolescents and young adults age 16-23 years not at increased risk for meningococcal disease.
Meningococcal Vaccination. The recommndation under the “Special Situations” subsection was updated to include use of the complement inhibitor ravulizumab as a situation for MenB administration. Also added was the recommendation to administer a booster dose of MenB 1 year after the primary series and revaccinate every 2-3 years if the risk remains.
Pneumococcal Vaccination. This secion has been updated with the revised recommendations for vaccination of immunocompetent adults age ≥65 years. One dose of PPSV23 is still recommended. Shared clinical decision-making is recommended regarding administration of PCV13 to immunocompetent persons age ≥65 years. A decision to administer PCV13 is made, it should be administered before PPSV23.
Tetanus, Diphtheria, & Pertussis Vaccination. The upate to this section indicates that Td or Tdap may be used in situations where only Td vaccine is indicated for the decennial tetanus, diphtheria, and pertussis booster vaccination, tetanus prophylaxis for wound management, and catch-up vaccination.
Varicella Vaccination. The update indicates that vaccination may be considered for persons with HIV without evidence of varicella immunity who have CD4 counts ≥200 cells/µL.
Links for Additional Information